PRODUCTS

qyQwRyxXltKVS

qyQwRyxXltKVS (6526)

17172

Not in at the moment vermox uk Aegis Capital Corp began coverage of the biotechnologycompany with a "buy" rating, saying preliminary data of itsbladder and lung cancer study could be out later in the year andpositive outcomes could make it a prime acquisition candidate.

Not in at the moment vermox uk Aegis Capital Corp began coverage of the biotechnologycompany with a "buy" rating, saying preliminary data of itsbladder and lung cancer study could be out later in the year andpositive outcomes could make it a prime acquisition candidate.

VAT Relief available

£7.00 Excluding VAT

£8.40 Including VAT

Website maintained by CIUK